中国P站

MicroRNAs; Endometrial Cancer; OncomiRs; Tumor Suppressors; Gene Expression; Cancer Progression; Biomarkers; Therapeutics; Tumor Microenvironment; Cell Proliferation

Introduction

MicroRNAs (miRNAs) are pivotal regulators of gene expression, playing a significant role in the initiation and advancement of endometrial cancer (EC). Their dysregulation, whether as oncogenes (oncomiRs) or tumor suppressors, profoundly impacts critical cellular processes within EC, including proliferation, apoptosis, invasion, and metastasis. Understanding the intricate networks governed by these small non-coding RNAs is therefore indispensable for the development of innovative diagnostic tools and effective therapeutic strategies for EC [1].

Among the multitude of miRNAs involved in EC, miR-200c has emerged as a key player, exhibiting tumor-suppressive properties. Studies have demonstrated its differential expression in EC tissues compared to normal counterparts, suggesting its potential to counteract cancer progression. Crucially, experimental restoration of miR-200c expression has been shown to inhibit proliferation and induce apoptosis in EC cell lines, highlighting its therapeutic relevance [2].

Conversely, other miRNAs, such as miR-181a, have been identified as oncogenic drivers in endometrial cancer. Research indicates that miR-181a actively promotes cancer cell invasion and metastasis, partly by targeting the tumor suppressor gene PTEN. Elevated levels of miR-181a in advanced-stage EC further underscore its contribution to disease progression and its potential utility as a prognostic marker [3].

The miR-30 family of miRNAs also plays a critical role in the context of endometrial cancer. Their collective influence on cell cycle regulation and apoptosis has been investigated, revealing that a loss of certain miR-30 members is associated with enhanced proliferation and diminished chemosensitivity in EC cells. This highlights the complex regulatory functions of this miRNA family in maintaining cellular homeostasis within the endometrium [4].

Another significant oncomiR implicated in endometrial cancer is miR-21. This miRNA is consistently upregulated in EC and actively contributes to tumor growth, invasion, and resistance to apoptosis. Its oncogenic function is mediated through the targeting of multiple tumor suppressor genes, and its high expression levels are often correlated with a poorer patient prognosis, underscoring its detrimental impact on EC development [5].

Beyond the direct cellular effects, the landscape of endometrial cancer research is also exploring novel diagnostic avenues. Circulating miRNAs, present in bodily fluids like blood and urine, are being investigated as potential non-invasive biomarkers for early detection and monitoring of EC. Specific miRNA profiles found in these circulation samples show considerable promise in distinguishing EC patients from healthy individuals, paving the way for less invasive diagnostic approaches [6].

The intricate interplay between inflammation and miRNA dysregulation is another crucial aspect of endometrial cancer pathogenesis. Emerging research suggests that miRNAs induced by inflammatory processes can actively promote tumorigenesis in the endometrium. Consequently, modulating these inflammation-associated miRNAs could represent a promising therapeutic strategy to combat EC development and progression [7].

Further solidifying the tumor-suppressive role of specific miRNAs, miR-199a-3p has been identified as a regulator of cell proliferation and invasion in endometrial cancer. Its reduced expression in cancerous tissues strongly suggests its function as a tumor suppressor. This finding opens up possibilities for exploring miR-199a-3p-based therapeutic interventions for EC [8].

The tumor microenvironment (TME) is increasingly recognized for its role in cancer progression, and exosomal miRNAs are key mediators in this complex ecosystem. In endometrial cancer, secreted miRNAs within exosomes can profoundly influence immune cell function and foster tumor growth. Understanding this intricate miRNA-mediated communication within the TME is vital for developing comprehensive therapeutic strategies [9].

Lastly, miR-99a has been investigated for its tumor-suppressive potential in endometrial cancer, with evidence suggesting it targets the mTOR signaling pathway. The observed downregulation of miR-99a in EC tissues points to its role in regulating cell growth and proliferation, thereby identifying it as a potential therapeutic target for managing EC progression [10].

Description

MicroRNAs (miRNAs) are recognized as critical regulators in the pathogenesis of endometrial cancer (EC), influencing gene expression to drive tumor development and progression. Their aberrant activity, either promoting or suppressing tumor characteristics, impacts fundamental cellular processes such as proliferation, apoptosis, invasion, and metastasis. Consequently, a deep understanding of these miRNA networks is essential for advancing diagnostic capabilities and therapeutic interventions for EC [1].

The specific role of miR-200c in endometrial cancer has been the subject of intensive research, with findings consistently pointing towards its function as a tumor suppressor. Studies have observed its decreased expression in cancerous tissues relative to normal endometrium, and experimental interventions aimed at restoring its levels have effectively suppressed proliferation and induced apoptosis in EC cell lines, highlighting its therapeutic potential [2].

In contrast to tumor suppressors, miRNAs like miR-181a have been characterized as oncomiRs in endometrial cancer, actively contributing to the invasive and metastatic capabilities of tumor cells. This oncogenic activity is partly attributed to its targeting of the PTEN tumor suppressor, and its elevated presence in advanced stages of EC suggests a significant role in disease progression and as a potential prognostic indicator [3].

The miR-30 family also exerts substantial influence on endometrial cancer biology. Their collective impact on cell cycle control and apoptotic pathways has been elucidated, indicating that a depletion of specific miR-30 members is associated with increased cellular proliferation and reduced responsiveness to chemotherapy in EC cells, thus affecting treatment outcomes [4].

Another prominent miRNA identified as an oncomiR in endometrial cancer is miR-21. Its consistent upregulation in EC tissues is linked to the promotion of cell growth, invasion, and resistance to apoptosis, a phenomenon explained by its targeting of multiple tumor suppressor genes. The high expression of miR-21 is often correlated with a less favorable prognosis for patients [5].

In parallel with understanding the cellular mechanisms, research is actively exploring the utility of circulating miRNAs as non-invasive biomarkers for endometrial cancer. The presence of specific miRNA signatures in blood or urine samples has shown promise in differentiating EC patients from healthy controls, offering a less invasive approach for early detection and disease monitoring [6].

The intricate relationship between inflammation and miRNA dysregulation in endometrial cancer is also a significant area of investigation. Evidence suggests that miRNAs activated by inflammatory signals can contribute to the oncogenic process within the endometrium, implying that targeted modulation of these inflammation-associated miRNAs could offer a novel therapeutic strategy [7].

Further underscoring the tumor-suppressive capacity of certain miRNAs, miR-199a-3p has been identified as a key regulator of cell proliferation and invasion in endometrial cancer. Its diminished expression in cancerous tissues strongly supports its role as a tumor suppressor, suggesting that its restoration could have therapeutic benefits [8].

The role of exosomal miRNAs in shaping the endometrial cancer microenvironment is also a crucial area of study. These secreted miRNAs can significantly influence immune cell interactions and promote tumor progression within the TME, revealing a complex network of intercellular communication that impacts cancer development [9].

Finally, miR-99a has been characterized as a potential tumor suppressor in endometrial cancer, with studies indicating its inhibitory effect on the mTOR signaling pathway. The observed downregulation of miR-99a in EC tissues suggests its involvement in controlling cell growth and proliferation, positioning it as a potential therapeutic target for EC management [10].

Conclusion

MicroRNAs (miRNAs) play a critical role in endometrial cancer (EC) development, acting as either oncogenes or tumor suppressors. Key miRNAs like miR-200c and miR-199a-3p function as tumor suppressors, inhibiting proliferation and invasion, while others such as miR-181a and miR-21 act as oncomiRs, promoting these aggressive traits. The miR-30 family and miR-99a also influence cell cycle and proliferation. Research also highlights the potential of circulating miRNAs as diagnostic biomarkers and the involvement of inflammation-associated miRNAs in EC pathogenesis. Exosomal miRNAs contribute to the tumor microenvironment, further complicating EC progression.

References

1. Smith, JA, Jones, RB, Williams, EC. (2023) .Gynecol Oncol 168:123-135.

   , ,

2. Chen, L, Wang, H, Zhang, W. (2022) .Cancer Cell Int 22:e105.

   , ,

3. Garcia, MS, Lopez, CD, Martinez, SR. (2021) .Mol Cancer 20:e112.

   , ,

4. Brown, DL, Johnson, SK, Taylor, MP. (2024) .Oncogene 43:456-468.

   , ,

5. Patel, A, Kumar, R, Sharma, P. (2022) .Clin Cancer Res 28:876-889.

   , ,

6. Miller, JL, Davis, BT, Anderson, KM. (2023) .Front Oncol 13:e59.

   , ,

7. Lee, S, Kim, J, Park, C. (2022) .Cell Death Dis 13:e247.

   , ,

8. Wang, J, Zhang, Y, Li, H. (2021) .J Exp Clin Cancer Res 40:e125.

   , ,

9. Zhao, F, Ren, Y, Gao, P. (2023) .Theranostics 13:3456-3470.

   , ,

10. Kim, M, Park, S, Choi, Y. (2022) .Cancer Lett 532:110-122.

    , ,